Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 30 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (1)
P 1 (4)
P 2 (16)
P 3 (2)

Trial Status

Recruiting17
Unknown6
Completed3
Not Yet Recruiting3
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT07040956Phase 2Recruiting

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

NCT06356584Phase 2Recruiting

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

NCT07032727Phase 2RecruitingPrimary

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

NCT07436845Recruiting

Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy

NCT07219940Phase 1Recruiting

A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects

NCT04821778Phase 3Recruiting

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

NCT07355764Phase 2Not Yet Recruiting

MA-CRC-II-016 SHR-1811

NCT04821843Phase 3Recruiting

Neoadjuvant Treatment Modalities in Esophageal Cancer

NCT04900935Not ApplicableRecruiting

Patient-centered, Optimal Integration of Survivorship and Palliative Care

NCT07230080Active Not Recruiting

Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer

NCT07198165Phase 2Recruiting

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

NCT06764680Phase 2Recruiting

Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer

NCT07010120Phase 1Recruiting

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

NCT06818097Completed

Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

NCT06971406Phase 2Not Yet Recruiting

High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

NCT06889649Phase 2Recruiting

SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC

NCT06741982Phase 1Recruiting

A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

NCT06694129Not Yet Recruiting

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

NCT06503380Recruiting

Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer

NCT06307249Phase 1Recruiting

Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

Scroll to load more

Research Network

Activity Timeline